Cellix Bio’s science of drug innovation:
Cellix Synergix platform technology utilizes existing knowledge of disease pathophysiology and creativity in adaptation of the pharmacologic properties of existing standard-of-care therapies and promising disease-modifying agents delivering novel therapies to the patients living with serious medical needs across our therapeutic areas of focus.
Cellix innovative platform is an effective methodology to drug design that focuses on creating new molecular entities with improved pharmacokinetic profile and synergistic pharmacology. Synergix aims to target known biomolecular pathophysiological pathways considered likely to yield significant therapeutic benefits as well as developing the structural molecular chemistry to optimize the New Molecular Entities (NMEs).
The NMEs are designed to be cleaved by specific enzymes exclusively within cells or by the mediation of specific intestinal enzymes in order to release the two bioactives independently and, therefore allowing the bioactives to reach their targets more efficiently and have greater efficacy and better PK-PD profile than if the bioactives were dosed independently or in combination.
Synergix platform technology has the capability to deliver both clinical and commercial successes. Our approach is unique and enables important functional capabilities through:
Synergix utilizes its existing expertise and know-how in unearthing of diverse pharmacology to reap substantial advantages in the drug development process. Some key benefits are: